Drugs / HRS-7058
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06383871 | Jun 2024 → Jun 2026 overdue | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07704645 | Aug 2026 → Jun 2028 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07589569 | Jun 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07503639 | Apr 2026 → Apr 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07032077 | Jul 2025 → Jun 2027 expected | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06915142 | Apr 2025 → Dec 2026 expected | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07601048 | Jun 2026 → May 2028 expected | — | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07704645 ↗ |
| Action | Inhibit | “KRAS G12C selective inhibitor” NCT07589569 ↗ |
| Target | KRAS | “KRAS G12C selective inhibitor” NCT07589569 ↗ |